Clinical Trial Update: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating obicetrapib alone and with Repatha (evolocumab) for lowering lipoprotein(a) levels in dyslipidemias; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• Obicetrapib (obicetrapib)
• Repatha (Evolocumab)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Dyslipidemias | Phase 2 | Status: RECRUITING